Literature DB >> 20638025

Chronic hepatitis B and hepatocellular carcinoma.

Amy C McClune1, Myron J Tong.   

Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world and the third leading cause of cancer-related deaths. More than 80% of HCC cases are from the Asian and African continents, and more than 50% of cases are from mainland China. Approximately 350 million to 400 million persons are chronically infected with hepatitis B virus (HBV), and this virus is the most common cause of HCC worldwide. It is estimated that more than 50% of liver cancers worldwide are attributable to HBV and up to 89% of HBV-related HCC are from developing countries. Recently, increasing trends in HCC incidence have been reported from several Western countries, including France, Australia, and the United States. 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20638025     DOI: 10.1016/j.cld.2010.05.009

Source DB:  PubMed          Journal:  Clin Liver Dis        ISSN: 1089-3261            Impact factor:   6.126


  25 in total

1.  Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008.

Authors:  Sean F Altekruse; Katherine A McGlynn; Lois A Dickie; David E Kleiner
Journal:  Hepatology       Date:  2012-02       Impact factor: 17.425

2.  An indel polymorphism in the 3' untranslated region of JAK1 confers risk for hepatocellular carcinoma possibly by regulating JAK1 transcriptional activity in a Chinese population.

Authors:  Qiang Yu; Weifeng Qian; Jian Wang; Yejiao Wu; Jinkun Zhang; Weichang Chen
Journal:  Oncol Lett       Date:  2018-03-26       Impact factor: 2.967

3.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

Review 4.  Risk factors for hepatocellular carcinoma.

Authors:  D Alan Herbst; K Rajender Reddy
Journal:  Clin Liver Dis (Hoboken)       Date:  2013-01-23

5.  Ultrasensitive quantification of hepatitis B virus A1762T/G1764A mutant by a SimpleProbe PCR using a wild-type-selective PCR blocker and a primer-blocker-probe partial-overlap approach.

Authors:  Hui Nie; Alison A Evans; W Thomas London; Timothy M Block; Xiangdong David Ren
Journal:  J Clin Microbiol       Date:  2011-05-11       Impact factor: 5.948

6.  Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study.

Authors:  Mohamed Abd El-Fattah; Mohamed Aboelmagd; Mohammed Elhamouly
Journal:  United European Gastroenterol J       Date:  2016-07-09       Impact factor: 4.623

7.  Quantification of complex precore mutations of hepatitis B virus by SimpleProbe real time PCR and dual melting analysis.

Authors:  Hui Nie; Alison A Evans; W Thomas London; Timothy M Block; Xiangdong David Ren
Journal:  J Clin Virol       Date:  2011-06-12       Impact factor: 3.168

8.  Screening serum biomarkers for early primary hepatocellular carcinoma using a phage display technique.

Authors:  Zhejia Zhang; Linyong Xu; Zhiming Wang
Journal:  J Clin Lab Anal       Date:  2011-11       Impact factor: 2.352

Review 9.  Progress in the treatment of pulmonary metastases after liver transplantation for hepatocellular carcinoma.

Authors:  Zhan-Wang Xiang; Lin Sun; Guo-Hong Li; Rakesh Maharjan; Jin-Hua Huang; Chuan-Xing Li
Journal:  World J Hepatol       Date:  2015-09-18

10.  Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine.

Authors:  Scott Bowden; Stephen Locarnini; Ting-Tsung Chang; You-Chen Chao; Kwang-Hyub Han; Robert G Gish; Robert A de Man; Miao Yu; Cyril Llamoso; Hong Tang
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.